Shimon Eckhouse, chairman of the board at Syneron, said in a statement that "As a global leading provider of medical aesthetic devices, we are pleased to expand into the skin whitening arena with our established track record in technological innovation."
The Elure whitening treatments are designed to treat uneven discoloration associated with aging and sun damage by eliminating darker pigmentation in the upper layers of the skin.
Syneron developed the products in conjunction with international cosmetics experts and scientists working in the fields of biotechnology and enzymes.
French-based DermaScan Laboratories carried out clinical trials of the product, where subjects used the products twice a day for 28 days.
According to the results, 82% of the subjects demonstrated a significant decrease in their melanin index, with 91% reporting an overall improvement in fairness and skin tone.
Studies also showed that the topical treatments delivered faster results when compared to several other products on the market, according to the company.
Elure will be available for sale throughout Asia in the first quarter of 2010 at dermatologists, beauty salons and spas.
Skin whitening is a beauty industry segment that has witnessed fast growth over the last few years. Euromonitor predicts that the global market will grow by over 10% annually, with major opportunities emerging from the rapidly expanding Asian markets, and the current market value is predicted to stand anywhere between $15 and $20bn.